Synthesis of a new series of pyrimidinyl-imidazo[2,1-b]thiazole derivatives is described. Their antiproliferative activity against A375 human melanoma cell line was tested and the effect of substituents on the pyrimidinyl ring side chain was investigated. The biological results indicated that most of the newly synthesized compounds showed moderate activity against A375, compared with Sorafenib. Among all of these derivatives, the cyclic sulfamide derivatives IIIa, IIIb, and IIIe showed the most potent antiproliferative activity against A375 human melanoma cell line. The IC50 values of compounds IIIa,b were in nanomolar scale. In addition, compound IIIe (IC50 = 1.9 µM) also demonstrated more potent antiproliferative activity compared with Sorafenib (IC50 = 5.6 µM).
Introduction
Much interest has been focused on the chemistry and the biological activity of imidazo [2,1-b] thiazole derivatives. Imidazo [2,1-b] thiazoles have been reported in the literature as antibacterial, 1 antifungal, 2 anthelmintic, 3, 4 and antitumor [5] [6] [7] [8] [9] agents. In addition, imidazo [2,1-b] thiazole derivatives demonstrated good antiproliferative activity against a variety of human cancer cell lines. [10] [11] [12] [13] [14] Recently, some pyrimidinyl substituted imidazo [2,1-b] thiazole derivatives have been reported as RAF kinases inhibitors. 15 It is well known that inhibitors of RAF kinases, such as Sorafenib, have demonstrated antiproliferative activity against different cancer types, such as melanoma. 16 Melanoma is the most aggressive form of skin cancer and is the fastest growing cancer in the United States. 17, 18 Early stage melanoma can be cured surgically. However, melanoma metastasizing to major organs (stage IV) is virtually incurable. 18 Patients with advanced melanoma have a median survival time of less than one year, and the estimated 5-years survival rate is less than 15%. 17, 19 With the incidence of melanoma rapidly rising in the United States and other developed countries, there is an urgent need to develop more effective drugs. carried out by reaction with sodium azide. Reduction of the azido group of 8 using PPh3/H2O afforded the corresponding amino compound 9, which was subsequently treated with the appropriate isocyanates to produce the corresponding urea derivatives 10a-d. Moreover, the amide derivatives 12a-j were obtained by condensation of 9 with the appropriate carboxylic acid derivatives using HOBt/EDCI/TEA. Deprotection of compounds 10a-d and 12a-j using H2/Pd-C afforded the corresponding amino compounds 11a-d and 13a-j, respectively (Scheme 2). The cyclic sulfamide reagents were prepared by the sequence of reactions illustrated in Scheme 3. Refluxing sulfamide (14) with the appropriate ethylenediamine derivatives in pyridine gave the cyclized products 15a-d. 26 Treatment of compounds 15a-d with compound 7 afforded the corresponding Cbz-protected compounds 16a-d. Deprotection of amino group of 16a-d using H2/Pd-C produced the desired N-(2-aminoethyl) cyclic sulfamide reagents 17a-d (Scheme 3).
Heating compound 4 with the previously prepared reagents 11a-d, 13a-j, or 17a-d in the presence of DIPEA produced the target compounds Ia-d, IIa-j, and IIIa-d, respectively (Scheme 4).
Compound IIIe (R = H) was prepared by deprotection of the N-Boc protected compound IIId using trifluoroacetic acid (Scheme 5).
In vitro activity. The antiproliferative activity of the newly synthesized compounds against A375P human melanoma cell line was examined. The ability of these compounds to inhibit the growth of A375 cell line is summarized in Tables 1-3 . Sorafenib was selected as a reference standard, because it has been extensively used in clinical trials for melanoma. 20, 27 As listed in Tables 1-3 , most of the compounds showed moderate activity, while compounds IIIa, IIIb, and IIIe exhibited the most potent antiproliferative activity against A375P human melanoma cell line, compared with Sorafenib. The IC50 values for compounds IIIa and IIIb were in nanomolar scale (0.60 µM and 0.38 µM, respectively), while the IC 50 value for compound IIIe was in micromolar scale (1.9 µM) but still more potent than Sorafenib (IC50 = 5.6 µM).
The compounds listed in Table 3 were more potent than those in Tables 1 and 2 . This suggests that the cyclic sulfamide moiety is more appropriate for activity, compared with urea and amide moieties. The constrained conformation of the 5-membered sulfamide ring may contribute to appropriate drug-receptor interaction, compared with flexible urea and amide moieties. In addition, the increased bulkness and lipophilicity produced by the ethylene moiety of the 5-membered ring may play a role in appropriate drug-receptor interaction.
Upon comparing the activities of compounds Ia and Ib, we find that introduction of an electron-donating group, methoxy group, at m-position of the terminal phenyl ring enhanced the activity. This may be attributed to the steric and/or electronic effects of methoxy group. In addition, compound Ib with m-methoxyphenyl moiety was more potent than compound Ic possessing m-(trifluoromethyl)phenyl moiety. So m-methoxyphenyl moiety was optimal for antiproliferative activity of the newly synthesized urea derivatives.
By comparing the activities of derivatives substituted with urea and amide moieties at the side chain as a linker, it was found that derivatives with urea moieties (Ia, Ib, and Id) were more potent than those with amide moieties (IIa, IId, and IIh). These results were seemed to indicate the effect of the linker on the activity.
Upon investigating the activities of cyclic sulfamide derivatives, we find that the potencies of compounds IIIe, IIIa, and IIIb possessing unsubstituted NH, N-methyl, and N-ethyl moieties, respectively, were in an increasing order. So introduction of alkyl groups on the terminal NH group of IIIe enhanced the activity. The longer the alkyl group (ethyl group, IIIb), the higher the potency than methyl group (IIIa). On the other hand, introduction of bulkier groups, benzyl or Boc (compounds IIIc and IIId, respectively) diminished the activity, compared with unsubstituted derivative IIIe. This increased bulkness may hinder the appropriate drug-receptor interaction.
Conclusion
A series of pyrimidinyl-imidazo[2,1-b]thiazole derivatives was synthesized based on our previous literature studies. Their antiproliferative activity against A375 human melanoma cell line was tested. Most of the newly synthesized compounds exhibited moderate antiproliferative activity against A375. Among all of these derivatives, the cyclic sulfamide derivatives IIIa, IIIb, and IIIe showed the most potent antiproliferative activity against A375 human melanoma cell line. The IC50 values of compounds IIIa,b were in nanomolar scale. In addition, compound IIIe showed more potent antiproliferative activity than Sorafenib but in micromolar scale. Further modification of these compounds in order to improve their potency is currently in progress. Our ultimate goal is to identify several compounds that are highly potent against melanoma cells.
Experimental Section
All melting points were obtained on a Walden Precision Apparatus Electrothermal 9300 apparatus and are uncorrected. Proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy was performed using either a Bruker ARX-300, 300 MHz spectrometer or a Bruker ARX-400, 400 MHz spectrometer (Bruker Bioscience, Billerica, MA, USA) with TMS as an internal standard. Unless otherwise noted, all solvents and reagents were commercially available and used without further purification. 
6-(4-Fluorophenyl)imidazo[2,1-b]thiazole (2)
.
6-(4-Fluorophenyl)-5-(2-(methylthio)pyrimidin-4-yl)imidazo[2,1-b]thiazole (3).
A mixture of compound 2 (6.0 g, 27.6 mmol), 4-iodo-2-(methylthio)pyrimidine (10.4 g, 41.3 mmol), cesium carbonate (13.4 g, 41.3 mmol), palladium acetate (1.22 g, 5.5 mmol), and triphenylphosphine (2.896 g, 11.04 mmol) in anhydrous DMF (60 mL) was stirred at 80 o C for 12 h. The mixture was cooled to room temperature and separated between ethyl acetate (150 mL) and water (200 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layer extracts were washed with brine, dried over anhydrous Na2SO4, and filtered. The organic solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography. The purified title product was obtained as white solid (3.5 g, 37%). mp 151 -152 o C; 
6-(4-Fluorophenyl)-5-(2-(methylsulfonyl)pyrimidin-4-yl) imidazo[2,1-b]thiazole (4).
To a solution of compound 3 (2.05 g, 6 mmol) in methanol (250 mL), a solution of oxone (12.3 g, 18 mmol) in water (50 mL) was added. The mixture was stirred at room temperature for 16 h. The organic solvent was evaporated under reduced pressure and the remaining aqueous solution was extracted with CH2Cl2 (50 mL) and the organic layer was separated. The aqueous layer was extracted with CH2Cl2 (3 × 25 mL) and the combined organic layer extracts were washed with brine, dried over anhydrous MgSO 4 , and filtered. The organic solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography. 2-(Benzyloxycarbonylamino)ethyl methanesulfonate (7). To a stirred solution of compound 6 (29.7 g, 152 mmol) in CH2Cl2 (300 mL) at 0 o C, TEA (31.58 mL, 227 mmol) was added dropwise. Methanesulfonyl chloride (14.1 mL, 182 mmol) was then added dropwise to the reaction mixture over 30 min. After completion of the addition, the mixture was stirred at 0 o C for 1 h. The mixture was quenched with water (300 mL) and extracted with CH2Cl2 (3 × 300 mL). The combined organic layer extracts were washed with brine, dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. Benzyl 2-aminoethylcarbamate (9). Triphenylphosphine (6.7 g, 25.56 mmol) and water (15 mL) were added to a solution of compound 8 (3.8 g, 17.4 mmol) in MeOH (40 mL). The mixture was heated under reflux for 2 h. The mixture was concentrated under reduced pressure and purified by column chromatography. The target product was obtained as light brown oil (3 g, 90%). 
1-(2-Aminoethyl)-3-phenylurea (11a).
Pd/C (0.05 g) was added to a solution of compound 10a (0.2 g, 0.52 mmol) in MeOH (10 mL). The mixture was stirred under hydrogen atmosphere at room temperature for 1 h. Pd/C was removed by celite filter, and the filtrate was evaporated under reduced pressure. 0.08 g of the title product was obtained and used in the next step without further purification (yield 85.8%).
Synthesis of compounds 11b-d was carried out by the same procedure as described for preparation of 11a. Synthesis of compounds 12b-j was carried out by the same procedure as described for preparation of 12a. In addition, synthesis of compounds 13a-j was carried out by the same procedure as described for preparation of 11a.
2-Methyl-1,2,5-thiadiazolidine-1,1-dioxide (15a). A solution of N-Methylethylenediamine (1.8 mL, 20.8 mmol) and sulfuric diamide (14, 2.0 g, 20.8 mmol) in pyridine (20 mL) was heated under reflux for 3 h. Toluene (5 mL) was added to the mixture and concentrated under vacuum. Water (20 mL) was added to the residue then extracted with ethyl acetate (3 × 20 mL). The combined organic layer extracts were washed with brine then dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography. The title product was obtained (1.5 g, 52.3%). C then compound 7 (1.5 g, 5.83 mmol) was added. The mixture was stirred at room temperature for 5 h then quenched with water (25 mL). The mixture was extracted with ethyl acetate (3 × 25 mL), the combined organic layer extracts were washed with brine, dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography. The desired product was obtained (0.82 g, 42.9%). 1,2,5-Thiadiazolidine, 2-methyl-, 5-aminoethyl-1,1-dioxide (17a). Pd/C (0.4 g) was added to a solution of compound 16a (0.82 g, 2.5 mmol) in MeOH (10 mL). The mixture was stirred under hydrogen atmosphere at room temperature for 1 h. Pd/C was removed by celite filter, and the filtrate was evaporated under reduced pressure. 0.44 g of the product 17a was obtained and used in the next step without further purification (yield 91%).
Synthesis of compounds 17b-d was carried out by the same procedure as described for preparation of 17a. .36 mmol) was added. The reaction mixture was stirred at the same temperature for 2 h, then allowed to warm to room temperature. The pH of the mixture was adjusted to 7 by dropwise addition of saturated NaHCO3 solution, and the mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layer extracts were washed with brine, dried over anhydrous Na2SO4, and filtered. Compound IIIe was obtained as a white solid (0.12 g, 73.2%). 
1-(2-(4-(6-(4-

